Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
出版年份 2018 全文链接
标题
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
作者
关键词
-
出版物
Nature Communications
Volume 9, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-04-17
DOI
10.1038/s41467-018-03951-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer
- (2017) Hui Fu et al. ONCOLOGY REPORTS
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
- (2016) Shawn F. Johnson et al. Cell Reports
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
- (2015) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
- (2013) Mo Li et al. CANCER CELL
- Sox2 promotes tamoxifen resistance in breast cancer cells
- (2013) Marco Piva et al. EMBO Molecular Medicine
- The BRCA1/BARD1-Interacting Protein OLA1 Functions in Centrosome Regulation
- (2013) Ayako Matsuzawa et al. MOLECULAR CELL
- Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan
- (2012) Stephen Hiscox et al. BMC CANCER
- Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway
- (2012) B. Ramaswamy et al. CANCER RESEARCH
- A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair
- (2012) Ko Sato et al. CURRENT BIOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
- (2012) A Ward et al. ONCOGENE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
- (2011) E. M. Fox et al. CANCER RESEARCH
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
- (2011) J. Baselga ONCOLOGIST
- Nuclear phosphoinositide 3-kinase controls double-strand break DNA repair
- (2010) A. Kumar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage
- (2009) Neil Johnson et al. MOLECULAR CELL
- Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy
- (2008) M. Rudas et al. CLINICAL CANCER RESEARCH
- Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
- (2008) D. Meijer et al. ENDOCRINE-RELATED CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started